DOP2014000034A - Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv) - Google Patents

Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)

Info

Publication number
DOP2014000034A
DOP2014000034A DO2014000034A DO2014000034A DOP2014000034A DO P2014000034 A DOP2014000034 A DO P2014000034A DO 2014000034 A DO2014000034 A DO 2014000034A DO 2014000034 A DO2014000034 A DO 2014000034A DO P2014000034 A DOP2014000034 A DO P2014000034A
Authority
DO
Dominican Republic
Prior art keywords
infections
hcv
hepatitis
virus
treatment
Prior art date
Application number
DO2014000034A
Other languages
English (en)
Spanish (es)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2014000034A publication Critical patent/DOP2014000034A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DO2014000034A 2011-08-19 2014-02-19 Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv) DOP2014000034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
DOP2014000034A true DOP2014000034A (es) 2014-06-01

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000034A DOP2014000034A (es) 2011-08-19 2014-02-19 Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)

Country Status (38)

Country Link
US (2) US8927593B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3199531A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6367712B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101913800B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103732065B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR087563A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012299295B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014002845A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2844086A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (2) CL2014000393A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO6862153A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140078A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1118399T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2744332T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2014000034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA032841B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2611731T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20161743T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE030300T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL230487B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CN00572A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3281B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2744332T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA35443B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME02588B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX354676B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20141201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014500385A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2744332T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2744332T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55462B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG10201606883QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2744332T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (2) SMT201700028T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI538915B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34274A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013028371A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201401020B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843502C (en) 2011-08-17 2019-01-15 Glaxosmithkline Llc Therapeutic methods for treating hepatitis c virus infection
WO2013028371A1 (en) 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
EP3218486A1 (en) 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Combination long acting compositions and methods for hepatitis c
CN107106489A (zh) * 2014-11-10 2017-08-29 葛兰素史克知识产权第二有限公司 用于丙型肝炎的长效药物组合物
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
ES2898217T3 (es) * 2017-03-02 2022-03-04 Assembly Biosciences Inc Compuestos de sulfamida cíclica y métodos de uso de los mismos
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
MX2022004912A (es) * 2019-10-25 2022-08-25 Sumitomo Pharma Co Ltd Novedoso compuesto de anillo condensado sustituido.
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
EP1355910B1 (en) 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
CA2504344A1 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2008051244A2 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
KR20150113219A (ko) 2006-02-16 2015-10-07 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
EP2015757A4 (en) * 2006-05-02 2011-01-26 Anacor Pharmaceuticals Inc HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP2011512341A (ja) * 2008-02-14 2011-04-21 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
WO2012067663A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
CA2843502C (en) * 2011-08-17 2019-01-15 Glaxosmithkline Llc Therapeutic methods for treating hepatitis c virus infection
WO2013028371A1 (en) 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
PH12014500385A1 (en) 2020-06-22
RS55462B1 (sr) 2017-04-28
JO3281B1 (ar) 2018-09-16
LT2744332T (lt) 2017-01-10
EP2744332B1 (en) 2016-10-26
SI2744332T1 (sl) 2017-01-31
KR101913800B1 (ko) 2018-11-01
BR112014002845A2 (pt) 2017-02-21
EP2744332A4 (en) 2015-01-14
HUE030300T2 (en) 2017-04-28
KR20140054287A (ko) 2014-05-08
CO6862153A2 (es) 2014-02-10
CN103732065B (zh) 2016-10-26
PE20141201A1 (es) 2014-10-03
DK2744332T3 (en) 2017-01-16
EA032841B1 (ru) 2019-07-31
TWI538915B (zh) 2016-06-21
CL2017000293A1 (es) 2017-10-06
ME02588B (me) 2017-06-20
MA35443B1 (fr) 2014-09-01
SG10201606883QA (en) 2016-10-28
US20150080343A1 (en) 2015-03-19
ZA201401020B (en) 2020-11-25
TW201321390A (zh) 2013-06-01
HRP20161743T1 (hr) 2017-02-24
SMT201700028T1 (it) 2017-03-08
PT2744332T (pt) 2017-01-24
AU2012299295B2 (en) 2016-03-31
US8927593B2 (en) 2015-01-06
JP2017125010A (ja) 2017-07-20
PL2744332T3 (pl) 2017-03-31
JP2014527529A (ja) 2014-10-16
AU2012299295A1 (en) 2014-02-20
SMT201700028B (it) 2017-03-08
MX2014001989A (es) 2014-02-27
CA2844086A1 (en) 2013-02-28
WO2013028371A1 (en) 2013-02-28
ES2611731T3 (es) 2017-05-10
AR087563A1 (es) 2014-04-03
US9682999B2 (en) 2017-06-20
MX354676B (es) 2018-03-15
EP3199531A1 (en) 2017-08-02
US20130237501A1 (en) 2013-09-12
IN2014CN00572A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-03
JP6367712B2 (ja) 2018-08-01
CN103732065A (zh) 2014-04-16
IL230487B (en) 2019-06-30
IL230487A0 (en) 2014-03-31
EA201490213A1 (ru) 2014-07-30
EP2744332A1 (en) 2014-06-25
CY1118399T1 (el) 2017-06-28
CR20140078A (es) 2014-03-20
UY34274A (es) 2013-04-05
CL2014000393A1 (es) 2014-08-01

Similar Documents

Publication Publication Date Title
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
ECSP18069924A (es) Compuestos tetracíclicos de piridona como antivirales
CL2017001769A1 (es) Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015).
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CO6561783A2 (es) Inhibidores del virus flaviviridae
ECSP14013315A (es) Inhibidores de aplicación viral
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
UY35362A (es) Compuestos terapéuticos
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
UY35263A (es) Compuestos terapéuticos
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
MX346143B (es) Ligandos del receptor ep1.
BR112014015582A8 (pt) compostos antivirais
BR112014013972A2 (pt) inibidores de hcv nssa
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
CO6771455A2 (es) Composición de inhibidor vírico para uso terapéutico in vivo
TH159902A (th) สารประกอบเบนโซฟิวแรนสำหรับรักษาการติดเชื้อไวรัสตับอักเสบ c
NI201400025A (es) Inhibidores de aplicación viral
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido